Literature DB >> 18415167

[Not Available].

M Zenz1.   

Abstract

Oral medication is the simplest way in treatment of chronic pain. For cancer pain oral analgesics are efficacious in more than 90% of the patients. When a causal therapy of pain (e.g. chemotherapy, operation) fails an analgesic ladder with oral analgesics is instituted. This ladder starts with a non-narcotic analgesic in a sufficient dose. The regular dose of acetylsalicylic acid or paracetamol is 4 g daily. When this dose does not work sufficiently, a weak opioid (e.g. dihydrocodeine) is given concomitantly at an individual dose. When the weak opioid fails, strong opioids are given (e.g. morphine). The drugs should be given by mouth whenever possible. The most important point is the regular application according to a time-schedule. This time-schedule is related to the action time of the drug. Patients with severe vomiting or dysphagia can receive a continuous subcutaneous infusion. These measures are based on recommendations of the WHO.The same medications can be employed in patients with chronic non-malignant pain, provided that all other conventional measures in pain treatment fail. However, many states of pain are not opioid-responsive. Pain related to the sympathetic nervous system is more responsive to antidepressants than to opioids or NSAID. Neuropathic pain as in trigeminal neuralgia responds to anticonvulsants. Pain from muscle spasm is better controlled by muscle relaxants than by analgesics. Bone pain is more sensitive to NSAID than to any other drug.In any state of pain the response to the different groups of drugs should be evaluated first. Then a stepwise pharmacological approach should be performed. In most cases pain can be treated effectively by oral drugs.

Entities:  

Year:  1991        PMID: 18415167     DOI: 10.1007/BF02530070

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  39 in total

1.  [Not Available].

Authors:  I Jurna
Journal:  Schmerz       Date:  1987-07       Impact factor: 1.107

2.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

3.  [Long-term therapy of cancer pain. A controlled study on buprenorphine].

Authors:  M Zenz; S Piepenbrock; M Tryba; M Glocke; M Everlien; W Klauke
Journal:  Dtsch Med Wochenschr       Date:  1985-03-22       Impact factor: 0.628

4.  Opioid pseudoaddiction--an iatrogenic syndrome.

Authors:  D E Weissman; J D Haddox
Journal:  Pain       Date:  1989-03       Impact factor: 6.961

5.  Antinociceptive effects of some alpha-sympathomimetic agents.

Authors:  H Schmitt; J C Le Douarec; N Petillot
Journal:  Neuropharmacology       Date:  1974-05       Impact factor: 5.250

6.  Addiction rare in patients treated with narcotics.

Authors:  J Porter; H Jick
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

7.  Transdermal fentanyl for pain control in patients with cancer.

Authors:  Angela W Miser; Prem K Narang; Judith A Dothage; Robert C Young; William Sindelar; James S Miser
Journal:  Pain       Date:  1989-04       Impact factor: 6.961

8.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

9.  Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord.

Authors:  G L Wilcox; K H Carlsson; A Jochim; I Jurna
Journal:  Brain Res       Date:  1987-03-03       Impact factor: 3.252

10.  [Caffeine plus analgesics-a significant combination.].

Authors:  J M Fox
Journal:  Schmerz       Date:  1988-12       Impact factor: 1.107

View more
  2 in total

1.  [Not Available].

Authors:  M Tschirner
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

2.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.